Aug 1 2006, 8:00 AM EST
News source: Business Wire
Optimer Pharmaceuticals, Inc. has named Kevin P. Poulos as Vice President of Marketing and Sales, a new position in the Company. Mr. Poulos has over 20 years of global and U.S. anti-infectives commercialization and product launch experience. In this position, he will be responsible for all marketing, sales and business development activities in preparation for the anticipated launch of the Company's pipeline compounds."Kevin's expertise in marketing and sales will be an exceptional asset as we prepare for the anticipated commercialization of our Phase 3 compounds. His experience and leadership in global and US infectious disease commercialization will be significant to Optimer as we build our anti-infectives portfolio," said Michael Chang, President of Optimer Pharmaceuticals, Inc.
Mr. Poulos' last position was with Wyeth Healthcare as Senior Director of New Products and Strategic Marketing. Prior to Wyeth, Mr. Poulos held senior marketing positions at Pharmacia-Upjohn Pharmaceuticals, Rhone-Poulenc Rorer Pharmaceuticals, Lederle Pharmaceuticals, and Beecham Pharmaceuticals. During his career, Mr. Poulos has lead the global commercialization activities of novel anti-infective classes and products such as Oxazolidinones (Zyvox(R)), Beta-lactamase inhibitor combinations (Zosyn(R)/Tazocin(R), Timentin(R)), Streptogramins (Synercid(R)), Quinolones (Zagam(R), Penetrex(R)), and extended spectum Penicillins (Pipracil(R)).
Mr. Poulos received his Business Administration degree in Marketing Management from Old Dominion University and is a member of the American Society of Microbiology.
Optimer Pharmaceuticals, Inc., a privately held biopharmaceutical company based in San Diego, CA, is focused on the development and global commercialization of anti-infective products for the treatment of serious infections. The Company also specializes in using its proprietary synthetic glycol-chemistry technology for drug discovery. More information can be found at www.optimerpharma.com
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to Optimer's plans to pursue clinical development of product candidates and timing and the potential efficacy of product candidates. Any statements contained in this press release that are not statements of fact may be deemed to be forward-looking statements. Words such as "plans," "intends," "expects" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Optimer's results to differ from those indicated by these forward-looking statements, including risks associated with the timing and success of pre-clinical studies and clinical trials.
ADVERTISEMENT
INTERVIEW:
(BIO) BANKING IN LUXEMBOURG - Interview with Robert Hewitt, Ph.D., CEO, Integrated Biobank of Luxembourg, and European Editor, Biopreservation and Biobanking (published by Mary Ann Liebert, Inc.)
...MORE
NewsArticles Blogs| Most Viewed | Most Emailed | Top Searches |
|---|---|---|
| Unclog the Innovation Bottleneck at our Nation’s Universities | ||
| (Bio) Banking in Luxembourg | ||
ADVERTISEMENT
Subscribe to RSS
Email
Print
Share
More News
Listen
Save
Comment
View All